PrediCareTM enables a treatment line switch just prior to an imminent disease progression. This policy adheres to the National Comprehensive Cancer Network (NCCN) guideline, e.g., for switch maintenance therapy in non-small cell lung cancer, but in contrast to the latter modality, PrediCareTM allows optimization of the timing of the switch in the treatment line, and thus contributes to better patient outcomes.

 

PrediCareTM integrates weak signals from multiple tumor markers, monitored during treatment, into a combined strong signal for approaching disease progression. This “signal amplifier” can herald an approaching disease progression in a patient and thus offers an improvement in the use of biomarkers over the present clinical practice in advanced cancer patients.